RCS - Argent Biopharma Ltd - Additional Information for Shareholders

Argent BioPharmaAnnouncement

16/12/2024 08:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241216:nRSP2117Qa&default-theme=true

RNS Number : 2117Q  Argent Biopharma Limited  16 December 2024

 

16 December 2024

 

Argent BioPharma Ltd.

(Argent BioPharma or the Company)

 

Additional Information for Shareholders

 

Argent BioPharma, an innovative multidisciplinary drug discovery company
within the biopharmaceutical sector, wishes to provide holders of the
Company's Depositary Interests (DIs) further information regarding their
shareholding following the Company's delisting from the Main Market of the
London Stock Exchange (LSE).

 

Upon the delisting event, Argent's shares will cease to be admitted to trading
on the LSE, removing the ability to trade through the exchange. The DIs will
still be able to settle through the CREST system, which will allow for the
depositary interests to be withdrawn from the CREST system and transferred
into the Clearing House Electronic Sub-register System (CHESS) which
facilitates trade settlements on the Australian Stock Exchange (ASX).  DI
holders will be contacted separately regarding any potential future
termination of the Depositary Interest facility but should note that in order
to settle any trades placed on the ASX they will need to withdraw their DIs
and reposition to CHESS, the process for which remains unchanged as a result
of the delisting.

 

The delisting is anticipated to be effective from 08:00 (GMT) on Tuesday, 31
December 2024. The last day of trading of Argent BioPharma shares on the LSE
will be Tuesday, 31 December 2024.

 

Any shareholder that has additional queries around trading is encouraged to
approach their investment adviser or broker.

 

-Ends-

 

Authorised for release by the board of directors, for further information
please contact:

 

 Argent BioPharma                                             Argent BioPharma

 Roby Zomer                                                   Rowan Harland

 CEO & Managing Director                                      Company Secretary

 +61 8 6555 2950                                              +61 8 6555 2950

 info@argentbiopharma.com (mailto:info@argentbiopharma.com)   info@argentbiopharma.co (mailto:info@argentbiopharma.co.uk) m

About Argent BioPharma

 

Argent BioPharma Limited (the "Company") (ASX: RGT; LSE: RGT; OTCQB: RGTLF) an
innovative multidisciplinary drug development Company within the
biopharmaceutical sector.  The Company focuses on multidisciplinary methods
with Nanotechnology, developing multi-target therapies for comprehensive
disease management, especially concerning the central nervous system ("CNS")
and Immunology treatments.

 

Follow us through our social media channels:

LinkedIn: Argent BioPharma

Twitter: @ArgentBioPharma

Facebook: Argent BioPharma

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAEAPAKFFALFEA